Clinical Trial

A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study investigates treatment of cadonilimab or placebo combined with SOX chemotherapy (oxaliplatin + tegafur-gimeracil-oteracil potassium) given before surgery (neoadjuvant) and cadonilimab or placebo combined with SOX chemotherapy after surgery (adjuvant), will work and be safe for the treatment of resectable (removable by surgery) gastric or gastroesophageal cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-10.
Status change: Not Yet Recruiting → Recruiting 2026-02-09
Trial Details
NCT Number NCT07023315
Lead Sponsor Akeso
Conditions Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Enrollment 760 participants
Start Date 2025-08-14
Primary Completion 2029-07 (estimated)
Study Completion 2031-07 (estimated)
Updated on ClinicalTrials.gov 2026-02-11